Hara Capital LLC Reduces Position in Bausch + Lomb Co. (NYSE:BLCO)

Hara Capital LLC decreased its stake in shares of Bausch + Lomb Co. (NYSE:BLCO) by 23.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,806 shares of the company’s stock after selling 2,355 shares during the period. Hara Capital LLC’s holdings in Bausch + Lomb were worth $141,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. increased its position in Bausch + Lomb by 68.3% during the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock worth $48,000 after buying an additional 1,004 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Bausch + Lomb during the fourth quarter worth $72,000. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bausch + Lomb during the third quarter worth $289,000. Polar Asset Management Partners Inc. acquired a new stake in shares of Bausch + Lomb during the third quarter worth $289,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Bausch + Lomb during the third quarter worth $302,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Trading Down 1.2 %

NYSE:BLCO opened at $16.44 on Tuesday. The business’s 50-day moving average is $17.59 and its two-hundred day moving average is $18.16. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. Bausch + Lomb Co. has a 12 month low of $13.16 and a 12 month high of $21.69. The firm has a market capitalization of $5.79 billion, a PE ratio of -15.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.46.

Analyst Upgrades and Downgrades

BLCO has been the topic of several analyst reports. Citigroup cut Bausch + Lomb from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $24.00 to $22.00 in a report on Wednesday, December 11th. Bank of America restated an “underperform” rating and set a $18.00 price objective on shares of Bausch + Lomb in a report on Thursday, December 12th. Wells Fargo & Company decreased their price objective on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Thursday, January 16th. Morgan Stanley cut Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a report on Monday, December 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Bausch + Lomb in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $20.25.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.